Wuxi, China
WuXi Biologics, established in 2000, is a leading global player in the Biotechnology industry, with its headquarters in China. As a spin-off from WuXi AppTec, the company has established a robust presence as a CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization), epitomized by its slogan, "WuXi Biologics - Discovery, Development, Manufacturing - CDMO - CMO”.
Anchored by a vision that "Every drug can be made and every disease can be treated", WuXi Biologics aims to build an open-access platform with comprehensive capabilities and technologies in the global biologics industry. The company's strategic expansion includes a total planned biopharmaceutical production capacity exceeding 430,000 liters across U.S., China, Ireland, Germany, and Singapore by 2024, cementing a premier-quality global supply chain network.
Its most recent significant financial milestone was an IPO investment on 01 June 2017, backed by Ally Bridge Group. This reflects investor confidence in its innovative approach, comprehensive service offerings, and ambitious growth trajectory. For investors, WuXi Biologics represents an attractive opportunity in biologics technology, driven by its leadership's commitment to accelerating the discovery, development, and manufacturing of biologics.
